Alto Neuroscience (NYSE:ANRO) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Alto Neuroscience (NYSE:ANRO) released its earnings results on Tuesday. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.13, FiscalAI reports.

Alto Neuroscience Trading Up 3.4%

Shares of NYSE:ANRO traded up $0.95 during trading on Tuesday, reaching $28.75. 515,791 shares of the stock were exchanged, compared to its average volume of 430,120. The firm’s 50-day moving average price is $26.84 and its 200 day moving average price is $24.37. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -11.88 and a beta of 1.42. Alto Neuroscience has a 12-month low of $10.80 and a 12-month high of $37.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85.

Wall Street Analysts Forecast Growth

ANRO has been the subject of several recent analyst reports. Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. BTIG Research increased their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Wedbush raised their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Finally, Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and an average price target of $37.88.

Insider Buying and Selling

In related news, CFO Nicholas Smith sold 110,830 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $26.58, for a total value of $2,945,861.40. Following the transaction, the chief financial officer owned 24,060 shares in the company, valued at approximately $639,514.80. This trade represents a 82.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 11.25% of the company’s stock.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.